Leinco is founded.
Tasuku Honjo and his team at Kyoto University discover the PD-1 immune checkpoint receptor and its role in programmed cell death.
FDA approves rituximab, for use in patients with B-Cell Non-Hodgkin Lymphoma. the first monoclonal antibody approved for use in cancer therapy
Following successful Phase 3 trials of 925 untreated metastatic colon cancer patients, the first VEGF-inhibitor is approved by the FDA.
Leinco Technologies licensed clone 9H10, Anti-mouse CTLA-4 from James Allison a future Nobel Prize winner.
Leinco upgraded to 4th state-of-the-art antibody and protein manufacturing facility with Missouri Governor Nixon in attendance.
Leinco Technologies became ISO9001 Certified as a requirement to manufacture raw materials for use in in vitro diagnostic devices.
Leinco Technologies licensed and added key checkpoint blockade antibodies like Clone RMP1-14. 9d9, C9B7W, and others.
Nobel Prize in Medicine to the two immunologists who were at the origin of the concept of ICI-based immunotherapy, James Allison and Tasuku Honjo.
Leinco released the first antibodies against SARS-CoV2 RBD which played an early and key role in mAb therapies. research and diagnostics of COVID19 disease.